Recent advances in stearoyl-CoA desaturase 1 inhibitors for dyslipidemia and obesity

Current Topics in Medicinal Chemistry

Volumn 10, Issue 4, 2010, Pages 419-433

  Liu, Gang ^a  

^a Ambit Biosciences   (United States)

Author keywords

Antisense oligonucleotide; Desaturation index; Dyslipidemia; Epidermal lipid barrier; Insulin resistance; Lipid metabolism; Meibomian gland; Mono unsaturated fatty acid; Obesity; Saturated fatty acid; Sebaceous gland; Stearoyl CoA desaturase

Indexed keywords

2 (PYRAZIN 2 YL)THIAZOLE; ACYL COENZYME A DESATURASE; ACYL COENZYME A DESATURASE INHIBITOR; ANTISENSE OLIGODEOXYNUCLEOTIDE; BENZIMIDAZOLE DERIVATIVE; LINOLEIC ACID; OXYGENASE INHIBITOR; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRIDAZINE DERIVATIVE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; SCD1 PROTEIN, HUMAN;

DRUG DESIGN; DRUG RESEARCH; DRUG TARGETING; DYSLIPIDEMIA; ENERGY EXPENDITURE; ENZYME ACTIVITY; ENZYME DEFICIENCY; HUMAN; IN VIVO STUDY; KNOCKOUT MOUSE; LIPOGENESIS; NONHUMAN; OBESITY; PROTEIN FUNCTION; REVIEW; RNA INTERFERENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DYSLIPIDEMIAS; METABOLIC DISEASES; MOUSE; STRUCTURE ACTIVITY RELATION;

ANIMALS; DYSLIPIDEMIAS; ENZYME INHIBITORS; HUMANS; METABOLIC DISEASES; MICE; OBESITY; STEAROYL-COA DESATURASE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77949481206     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610790980594     Document Type: Review

References (96)

1. Miyazaki, M.; Ntambi, J. M. Role of stearoyl-coenzyme a desaturase in lipid metabolism. Prostaglandins Leukot. Essent. Fatty Acids, 2003, 68, 113-121.
2. Enoch, H. G.; Catala, A.; Strittmatter, P. Mechanism of Rat Liver Microsomal Stearyl-CoA Desaturase. Studies of the substrate specificity, enzyme-substrate interactions, and the function of lipid. J. Biol. Chem., 1976, 251, 5095-5103.
3. Dobrzyn, A.; Ntambi, J. M. The role of stearoyl-CoA desaturase in body weight regulation. Trends Cardiovasc. Med., 2004, 14, 77-81.
4. Kaestner, K. H.; Ntambi, J. M.; Kelly, T. J. Jr.; Lane, M. D.; Differentiation-induced gene expression in 3T3-L1 preadipocytes. a second differentially expressed gene encoding stearoyl-CoA desaturase. J. Biol. Chem., 1989, 264, 14755-14761.
5. Zheng, Y.; Prouty, S. M.; Harmon, A.; Sundberg, J. P.; Stenn, K. S.; Parimoo, S. SCD3 - A novel gene of the stearoyl-CoA desaturase family with restricted expression in skin. Genomics, 2001, 71, 182-191.
6. Miyazaki, M.; Jacobson, M. J.; Man, W. C.; Cohen, P.; Asilmaz, E.; Friedman, J. M.; Ntambi, J. M. Identification and characterization of murine SCD4, a novel heart-specific stearoyl-CoA desaturase isoform regulated by leptin and dietary factors. J. Biol. Chem., 2003, 278, 33904-33911.
7. Zhang, L.; Ge, L.; Parimoo, S.; Stenn, K.; Prouty, S.M. Human stearoyl-CoA desaturase: Alternative transcripts generated from a single gene by usage of tandem polyadenylation sites. Biochem. J., 1999, 340, 255-264.
8. Beiraghi, S.; Zhou, M.; Talmadge, C. B.; Went-Sumegi, N.; Davis, J. R.; Huang, D.; Saal, H.; Seemayer, T. A.; Sumegi, J. Identification and characterization of a novel gene disrupted by a pericentric inversion Inv(4)(P13.1q21.1) in a family with cleft lip. Gene, 2003, 309, 11-21.
9. Zheng, Y.; Eilertsen, K. J.; Ge, L.; Zhang, L.; Sundberg, J. P.; Prouty, S. M.; Stenn, K. S.; Parimoo, S. SCD1 is expressed in sebaceous glands and is disrupted in the asebia mouse. Nat. Genet., 1999, 23, 268-270.
10. Ntambi, J. M.; Miyazaki, M.; Stoehr, J. P.; Lan, H.; Kendziorski, C. M.; Yandell, B. S.; Song, Y.; Cohen, P.; Friedman, J. M.; Attie, A. D. Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc. Natl. Acad. Sci. USA, 2002, 99, 11482-11486.
11. Rahman, S. M.; Dobrzyn, A.; Dobrzyn, P.; Lee, S. H.; Miyazaki, M.; Ntambi, J. M. Stearoyl-CoA desaturase 1 deficiency elevates insulin-signaling components and down-regulates protein-tyrosine phosphatase 1B in muscle. Proc. Natl. Acad. Sci. USA, 2003, 100, 11110-11115.
12. Dobrzyn, P.; Dobrzyn, A.; Miyazaki, M.; Cohen, P.; Asilmaz, E.; Hardie, D. G.; Friedman, J. M.; Ntambi, J. M. Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver. Proc. Natl. Acad. Sci. USA, 2004, 101, 6409-6414.
13. Dobrzyn, A.; Dobrzyn, P.; Lee, S.-H.; Liyazaki, M.; Cohen, P.; Asilmaz, E.; Hardie, D. G.; Friedman, J. M.; Ntambi, J. M. Steroyl-CoA desaturase-1 deficiency rduces ceramide synthesis by downregulating serine palmitoyltransferase and increasing Betaoxidation in skeletal muscle. Am. J. Physiol. Endocrinol. Metab., 2005, 288, E599-607.
14. Miyazaki, M.; Kim, Y. C.; Gray-Keller, M. P.; Attie, A. D.; Ntambi, J. M. The biosynthesis of hepatic cholesterol esters and triglycerides is impaired in mice with a disruption of the gene for stearoyl-CoA desaturase 1. J. Biol. Chem., 2000, 275, 30132-30138.
15. Miyazaki, M.; Kim, H. J.; Man, W. C.; Ntambi, J. M. Oleoyl-CoA is the major de novo product of stearoyl-CoA desaturase 1 gene isoform and substrate for the biosynthesis of the harderian gland 1-Alkyl-2,3-diacylglycerol. J. Biol. Chem., 2001, 276, 39455-39461.
16. Jiang, G.; Li, Z.; Liu, F.; Ellsworth, K.; Dallas-Yang, Q.; Wu, M.; Ronan, J.; Esau, C.; Murphy, C.; Szalkowski, D.; Bergeron, R.; Doebber, T.; Zhang, B. B. Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1. J. Clin. Invest., 2005, 115, 1030-1038.
17. Gutierrez-Juarez, R.; Pocai, A.; Mulas, C.; Ono, H.; Bhanot, S.; Monia, B. P.; Rossetti, L. Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of diet-induced hepatic insulin resistance. J. Clin. Invest., 2006, 116, 1686-1695.
18. Xu, H.; Wilcox, D.; Nguyen, P.; Voorbach, M.; Smith, H.; Brodjian, S.; Suhar, T.; Reilly, R. M.; Jacobson, P. B.; Collins, C. A.; Landschulz, K.; Surowy, T. K. Hepatic knockdown of stearoyl-CoA desaturase 1 via RNA interference in obese mice decreases lipid content and changes fatty acid composition. Front. Biosci., 2007, 12, 3781-3794.
19. Rahman, S. M.; Dobrzyn, A.; Lee, S. H.; Dobrzyn, P.; Miyazaki, M.; Ntambi, J.M. stearoyl-CoA desaturase 1 deficiency increases insulin signaling and glycogen accumulation in brown adipose tissue. Am. J. Physiol. Endocrinol. Metab., 2005, 288, E381-387.
20. (a) Wang, J.; Yu, L.; Schmidt, R. E.; Su, C.; Huang, X.; Gould, K.; Cao, G. Characterization of HSCD5, a novel human stearoyl-CoA desaturase unique to primates. Biochem. Biophys. Res. Commun., 2005, 332, 735-742.
21. (b) Zhang, S.; Yang, Y.; Shi, Y. Characterization of human SCD2, an oligomeric desaturase with improved stability and enzyme activity by cross-linking in intact cells. Biochem. J., 2005, 388 (Pt 1), 135-142.
22. Attie, A. D.; Krauss, R. M.; Gray-Keller, M. P.; Brownlie, A.; Miyazaki, M.; Kastelein, J. J.; Lusis, A. J.; Stalenhoef, A. F.; Stoehr, J. P.; Hayden, M. R.; Ntambi, J. M. Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia. J. Lipid Res., 2002, 43, 1899-1907.
23. Mar-Heyming, R.; Miyazaki, M.; Weissglas-Volkov, D.; Kolaitis, N. A.; Sadaat, N.; Plaisier, C.; Pajukanta, P.; Cantor, R. M.; de Bruin, T. W.; Ntambi, J. M.; Lusis, A. J. Association of stearoyl-CoA desaturase 1 activity with familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol., 2008, 28, 1193-1199.
24. Hulver, M. W.; Berggren, J. R.; Carper. M. J.; Miyazaki, M.; Ntambi, J. M.; Hoffman, E. P.; Thyfault, J. P.; Stevens, R.; Dohm, G. L.; Houmard, J. A.; Muoio, D. M. Elevated stearoyl-CoA desaturase-1 expression in skeletal muscle contributes to abnormal fatty acid partitioning in obese humans. Cell Metab., 2005, 2, 251-261.
25. Stefan, N.; Peter, A.; Cegan, A.; Staiger, H.; Machann, J.; Schick, F.; Claussen, C. D.; Fritsche, A.; Häring, H.-U.; Schleicher, E. Low Hepatic stearoyl-CoA desaturase 1 activity is associated with fatty liver and insulin resistance in obese humans. Diabetologia, 2008, 51, 648-656.
26. Steinar, S.; Hilde, N.; Sørensen, L. N.; Larsen, H. H.; Steineger, K. H.; ∅ystein, S.; Spydevold, R. H.; Jon, B. Thia fatty acids, metabolism and metabolic effects. Biochim. Biophys. Acta, 1997, 1344, 115-131.
27. Gomez, F. E.; Bauman, D. E.; Ntambi, J. M.; Fox, B. G. Effects of sterculic acid on stearoyl-CoA desaturase in differentiating 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun., 2003, 300, 316-326.
28. Ntambi, J. M. Regulation of stearoyl-CoA desaturase by polyunsaturated fatty acids and cholesterol. J. Lipid Res., 1999, 40, 1549-1558.
29. (a) Abreo, M.; Chafeev, M.; Chakka, N.; Chowdhury, S.; Fu, J.-M.; Gschwend, H. W.; Holladay, M. W.; Hou, D.; Kamboj, R.; Kodumuru, V.; Li, W.; Liu, S.; Raina V.; Sun, S.; Sun, S.; Sviridov, S.; Tu, C.; Winther, M. D; Zhang, Z. Pyridazine derivatives and their use as therapeutic agents. WO2005/011655, 2005.
30. (b) Sviridov, S.; Kodumuru, V.; Liu, S.; Abreo, M.; Winther, M. D.; Gschwend, H. W.; Kamboj, R.; Sun, S.; Holladay, M. W.; Li, W.; Tu, C. Piperazine derivatives and their use as therapeutic agents. WO 2005/011657, 2005.
31. Fu, J.-M.; Kodumuru, V.; Sun, S.; Winther, M. D.; Fine, R. M.; Harvey, D. F.; Klebansky, B.; Gray-Keller, M. P.; Gschwend, H. W.; Li, W. Nicotinamide derivatives and their use as therapeutic agents. US2005/0119251, 2005.
32. Fu, J.-M.; Kodumuru, V.; Sun, S.; Winther, M. D.; Fine, R. M.; Harvey, D. F.; Klebansky, B.; Gray-Keller, M. P.; Gschwend, H. W. Nicotinamide derivatives and their use as therapeutic agents. WO2006/014168, 2006.
33. Kamboj, R.; Zhang, Z.; Sviridov, S.; Raina, V.; Hou, D.; Kodumuru, V.; Seid Bagherzadeh, M.; Roth, C. J.; Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors. WO2006/034441, 2006.
34. Kamboj, R.; Fu, J.-M.; Kodumuru, V.; Liu, S.; Sadalapure, K.; Chakka, N.; Hou, D.; Sun, S. Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-CoA-desaturase (SCD). WO2006/034312, 2006.
35. Kamboj, R.; Zhang, Z.; Fu, J.-M.; Kodumuru, V.; Liu, S.; Sun, S.; Chakka, N. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes. WO2006/034315, 2006.
36. Sun, S.; Zhang, Z.; Roth, C. J.; Piperazine derivatives and their uses as therapeutic agents. WO2006/125194, 2006.
37. Fu, J.-M.; Liu, S. Thiazolidine derivatives and their uses as therapeutic agents. WO2007/046868, 2007.
38. Fu, J.-M.; Kodumuru, V.; Sviridov, S. Fused piperidine derivatives and their uses as therapeutic agents. WO/2007/050124, 2007.
39. Kamboj, R.; Zhang, Z.; Fu, J.-M.; Seid Bagherzadeh, M.; Sviridov, S.; Chowdhury, S.; Liu, S.; Kodumuru, V. Heterocyclic derivatives and their use as therapeutic agents. WO2006/034279, 2006.
40. Kamboj, R.; Zhang, Z.; Fu, J.-M.; Sviridov, S.; Sun. S.; Seid Bagherzadeh, M.; Raina, V.; Hou, D.; Chowdhury, S.; Liu, S.; Kodumuru, V.; Chakka, N. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase. WO2006/034338, 2006.
41. Fu, J.-M.; Kodumuru, V.; Liu, S. Piperidine derivatives and their use as Stearoyl-CoA desaturase modulators. WO2006/125181, 2006.
42. Chowdhury, S.; Roth, C. J. Heteroaryl compounds and their uses as therapeutic agents. WO2007/044085, 2007.
43. Kodumuru, V.; Roth, C. J. Piperidine derivatives and their uses as therapeutic agents. WO2007/046867, 2007.
44. Kamboj, R.; Zhang, Z.; Fu, J.-M.; Sviridov, S.; Chowdhury, S.; Liu, S.; Kodumuru, V.; Pyridazine derivatives for inhibiting human stearoyl-CoA- desaturase. WO2006/034341, 2006.
45. Kamboj, R.; Zhang, Z.; Fu, J.-M.; RAINA, V.; Sviridov, S.; Kodumuru, V.; Chakka, N.; Liu, S.; Sun, S.; Hou, D. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors. WO2006/101521, 2006.
46. Fu, J.-M.; Kodumuru, V.; Sviridov, S. Tricyclic compounds and their uses as therapeutic agents. WO2006/125179, 2006.
47. Kamboj, R.; Zhang, Z.; Fu, J.-M.; Kodumuru, V.; Sviridov, S.; Sadalapure, K.; Liu, S.; Sun. S.; Hou, D.; Chakka, N. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors. WO2006/034440. 2006.
48. Kamboj, R.; Kodumuru, V.; Roth, C. J. Pyridine derivatives for inhibiting human stearoyl-CoA-desaturase. WO2006/034446, 2006.
49. Hou, D.; Roth, C. J. Tricyclic pyridazine compounds and their uses as therapeutic agents. WO2006/125178. 2006.
50. Fu, J.-M.; Liu, S. Piperazine derivatives and their uses as therapeutic agents. WO2006/125180, 2006.
51. Chowdhury, S.; Zhang, Z. Macrocyclic compounds and their uses as stearoyl-CoA desaturase. WO2007/136746, 2007.
52. Fu, J.-M.; Hou, D.; Kamboj, R.; Kodumuru, V.; Pokrovskaia, N.; Raina, V.; Sun, S.; Sviridov, S.; Zhang, Z. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors. WO2007/130075, 2007.
53. Dales, N.; Fonarev, J.; Fu, J.-M.; Hou, D.; Kamboj, R.; Kodumuru, V.; Pokrovskaia, N.; Raina, V.; Sun, S.; Zhang, Z. Organic compounds. WO2007/143597, 2007.
54. Dales, N.; Zhang, Z.; 2-(Pyrazin-2-yl)-thiazole and 2-(1H-Pyrazol-3-yl)- thiazole derivatives as well as related compounds as stearoyl-CoA desaturase (SCD) inhibitors for the treatment of metabolic, cardiovascular and other disorders. WO2008/024390, 2008.
55. Dales, N.; Zhang, Z.; Kamboj, R.; Fu, J.-M.; Sun, S.; Pokrovskaia, N.; Sviridov, S. Heterocylic organic compounds. WO/2008/036715, 2008.
56. Dales, N.; Zhang, Z.; Fonarev, J.; Fu, J.M.; Kamboj, R.; Kodumuru, V.; Pokrovskaia, N.; Sun, S. 2-Substituted 5-membered heterocycles as SCD inhibitors. WO2008/074835, 2008.
57. Dales, N.; Fonarev, J.; Fu, J.; Kamboj, R. Kodumuru, V.; Liu, S.; Pokrovskaia, N.; Raina, V.; Sun, S.; Zhang, Z. Organic compounds, WO/2008/127349, 2008.
58. Li, C. S.; Ramtohul, Y.; Huang, Z.; Lachance, N. Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase. WO2006/130986, 2006.
59. Black, C.; Deschenes, D.; Gagnon, M.; Lachance, N.; Leblanc, Y.; Leger, S.; Chun, S. L.; Oballa, R. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase. WO2007/009236, 2007.
60. Crane, S.; Robichaud, Joel, S.; Leger, S.; Ramtohul, Y. Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase. WO2007/056846, 2007.
61. Ramtohul, Y. Azacycloalkane derivatives as inhibitors of stearoylcoenzyme a delta-9 desaturase. WO2008/017161, 2008.
62. Leblanc, Y.; Gagnon, M. Cyclic amine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase. WO2007/134457, 2007.
63. Isabel, E.; Oballa, R.; Powell, D.; Robichaud, J. Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase. WO2007/143823, 2007.
64. Li, C., S.; Ramtohul, Y. K. Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase. WO/2007/143824, 2007.
65. Oballa, R. M.; Deschenes, D.; Gagnon, M.; Leblanc, Y.; Powell, D.; Ramtohul, Y., K. Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase WO2008/046226, 2008.
66. Lachance, N.; Li, C., S.; Leclerc, J.-P.; Ramtohul, Yeeman, K. Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase. WO2008/064474, 2008.
67. Liu, G.; Lynch, J. K.; Freeman, J.; Liu, B.; Xin, Z.; Zhao, H.; Serby, M. D.; Kym, P. R.; Suhar, T. S.; Smith, H. T.; Cao, N.; Yang, R.; Janis, R. S.; Krauser, J. A.; Cepa, S. P.; Beno, D. W.; Sham, H. L.; Collins, C. A.; Surowy, T. K.; Camp, H. S. Discovery of potent, selective, orally bioavailable stearoyl-coa desaturase 1 inhibitors. J. Med. Chem., 2007, 50, 3086-3100.
68. Zhao, H.; Serby, M. D.; Smith, H. T.; Cao, N.; Suhar, T. S.; Surowy, T. K.; Camp, H. S.; Collins, C. A.; Sham, H. L.; Liu, G. Discovery of 1-(4-phenoxypiperidin-1-yl)-2-arylaminoethanone stearoyl-CoA desaturase 1 inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 3388-3391.
69. Xin, Z.; Zhao, H.; Serby, M. D.; Liu, B.; Liu, M.; Szczepankiewicz, B. G.; Nelson, L. T.; Smith, H. T.; Suhar, T. S.; Janis, R. S.; Cao, N.; Camp, H. S.; Collins, C. A.; Sham, H. L.; Surowy, T. K.; Liu, G. Discovery of piperidine-aryl urea-based stearoyl-CoA desaturase 1 inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 4298-4302.
70. Zilbershtein, T.; Cole, A.; Zablocki, J.; Koltun, D.; Chisholm, J.; Glushkov, A.; Vasilevich, N.; Henderson, I.; Lin, T.; Parkhill, E. Pteridinone derivatives for use as stearoyl CoA desaturase inhibitors. WO2008/123891, 2008.
71. Zablocki, J.; Glushkov, A.; Zilbershtein, T.; Parkhill, E.; Koltun, D.; Vasilevich, N.; Chisholm, J.; Vanov, A. Bicyclic nitrogencontaining heterocyclic compounds for use as stearoyl CoA desaturase inhibitors. WO2008/043087, 2008.
72. Koltun, D.; Parkhill, E.; Boze, M.; Zablocki, J.; Vasilevich, N.; Glushkov, A.; Cole, A.; Mayboroda, E.; Chisholm, J. 3-Hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors. WO2008/127615, 2008.
73. Koltun, D. O.; Parkhill, E. Q.; Vasilevich, N. I.; Glushkov, A. I.; Zilbershtein, T. M.; Ivanov, A. V.; Cole, A. G.; Henderson, I.; Zautke, N. A.; Brunn, S. A.; Mollova, N.; Leung, K.; Lawn, R.; Chisholm, J. W.; Zablocki, J. Potent, selective, and metabolically stable stearoyl-CoA desaturase (SCD) inhibitors for the potential treatment of obesity and diabetes. The 236 th ACS National Meeting, Philadelphia, PA, August 2008.
74. Daugan, A. C.-M.; Dean, A. W. Compounds, WO2008/074824, 2008.
75. Bouillot, A. M. J.; Daugan, A. C.-M.; Dean, A. W.; Fillmore, M. C. Compounds, WO2008/074832, 2008.
76. Daugan, A. C.-M. Compounds, WO2008/074833, 2008.
77. Daugan, A. C.-M. Compounds, WO2008/074834, 2008.
78. Bouillot, A. M. J.; Boyer, T.; Daugan, A. C.-M.; Dean, A. W.; Fillmore, M. C.; Lamotte, Y. Thiadiazole derivatives, inhibitors of stearoyl-CoA desaturase, WO2008/104524, 2008.
79. Taniguchi, T.; Miyata, K.; Kubo, O.; Matsui, J. Preparation of aromatic amine derivatives as stearoyl-CoA desaturase (SCD) inhibitors. WO2008/044767, 2008.
80. Taniguchi, T.; Miyata, K.; Kubo, O. Preparation of pyridazine ringcontaining spiro compounds as stearoyl-CoA desaturase inhibitors for treatment of obesity, diabetes, etc. WO2008/096746, 2008.
81. Uto, Y.; Kiyotsuka, Y. Preparation of spiropiperidine derivatives as stearoyl-CoA-desaturase inhibitors. WO2008/056687, 2008.
82. Iida, T.; Ubukata, M.; Mitani, I.; Nakagawa, Y.; Tanaka, M. Five-membered cyclic amide compound and use thereof. WO2008/120744, 2008.
83. Iida, T.; Mitani, I.; Nakagawa, Y.; Tanaka, M.. Six-membered amide compound and use thereof. WO2008/123469, 2008.
84. Ubukata, M.; Maeda, K.; Iida, T.; Mitani, I. Urea compound and use thereof. WO2008/120759, 2008.
85. Thomas, A.; Lingam, V.S. P. R.; Chaudhari, S. S.; Khairatkar-Joshi, N.; Shah, D. M. Preparation of oxazolanones as therapeutic stearoyl coa desaturase inhibitors. WO2008/029266, 2008.
86. Thomas, A.; Lincam, V. S. P. R.; Phatangare, S. K.; Khairatkar-Joshi, N.; Shah, D. M.; Ukirde, D. V.; More, D. A. Acetylene derivatives as stearoyl CoA desaturase inhibitors and their preparations, pharmaceutical compositions and use in the treatment of diseases. WO2008/062276, 2008.
87. Lundbaeck, T.; Climent-Johansson, I.; Vaagberg, J.; Bremberg, U.; Linden, A.; Nilsson, J.; Wiik, M. Preparation of pyrazolo[1,5-a]pyrimidine derivatives for use as inhibitors of stearoyl-CoA desaturase (SCD) activity. WO2008/003753, 2008.
88. Bremberg, U.; Linden, A.; Lundbaeck, T.; Nilsson, J.; Wiik, M.; Bergner, M.; Brandt, P.; Hammer, K.; Ringom, R. Preparation of pyrazolo[1,5-a]Pyrimidines as inhibitors of stearoyl-CoA desaturase. WO2008/116898, 2008.
89. Liu, G. Stearoyl-CoA desaturase-1 (SCD1) Inhibitors: discovery and in vivo evaluation, emerging targets for type 2 diabetes symposium, The 233th ACS national meeting, Chicago, IL, March 2007.
90. Mika, A.; Adler, A.; Farb, T.; Antonucci, L.; Xin, Z.; Lisowski, A.; Blomme, E.; Surowy, T.; Liu, G.; Camp H.; Brune M. Effects of small molecule inhibition of stearoyl-CoA desaturase-1 in the high fat fed diabetic female ZDF rat. 2007. ADA Meeting 67th Scientific Sessions, Chicago, IL, June, 2007.
91. Kamboj, R.; Winther, M.; Fraser, R.; Chafeev, M.; Chowdhury, S.; Fu, J.-M.; Hou, D.; Liu, S.; Raina, V.; Seid Bagherzadeh, M.; Sviridov, S.; Sadalapure, K.; Sun, S.; Kodumuru, V.; Chakka, N.; Zhang, Z.; Abreo, M.; Kondratenko, M, A.; Harvey, D. F.; Hudson, C. J.; Li, W.; Tu, C.; Sun, S. Holladay, M. W.; Gschwend, H. W. Combination therapy. WO2006/086445, 2006.
92. Miyazaki, M.; Man, W. C.; Ntambi, J. M. Targeted disruption of stearoyl-CoA desaturase1 gene in mice causes atrophy of sebaceous and meibomian glands and depletion of wax esters in the eyelid. J. Nutr., 2001, 131, 2260-2268.
93. Binczek, E.; Jenke, B.; Holz, B.; Günter, R. H.; Thevis, M.; Stoffel, W. Obesity resistance of the stearoyl-CoA desaturase-deficient (SCD1-/-) mouse results from disruption of the epidermal lipid barrier and adaptive thermoregulation. Biol. Chem., 2007, 388, 405-418.
94. Miyazaki, M.; Flowers, M. T.; Sampath, H.; Chu, K.; Otzelberger, K.; Liu, X.; Ntambi J. M. Hepatic stearoyl-CoA desaturase-1 deficiency protects mice from carbohydrate-induced adiposity and hepatic steatosis. Cell Metab., 2007, 6, 484-496.
95. Brown, J. M.; Chung, S.; Sawyer, J. K.; Degirolamo, C.; Alger, H. M.; Nguyen, T.; Zhu, X.; Duong, M. N.; Wibley, A. L.; Shah, R.; Davis, M. A.; Kelley, K.; Wilson, M. D.; Kent, C.; Parks, J. S.; Rudel, L. L. Inhibition of stearoyl-coenzyme a desaturase 1 dissociates insulin resistance and obesity from atherosclerosis. Circulation, 2008, 118, 1467-1475.
96. Peter, A.; Weigert, C.; Staiger, H.; Rittig, K.; Cegan, A.; Lutz, P.; Machicao, F.; Häring, H. U.; Schleicher, E. Induction of stearoyl-CoA desaturase protects human arterial endothelial cells against lipotoxicity. Am. J. Physiol. Endocrinol. Metab., 2008, 295, E339-349.